News
WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE ® (pegcetacoplan injection) preserved visual function at 36 months in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback